Carolyn Bertozzi

Carolyn R.
Bertozzi founded Redwood Bioscience, Inc. in 2008, TwoStep Therapeutics, Inc. in 2024, Palleon Pharmaceuticals, Inc. in 2015, Venn Biosciences Corp.
in 2017, Lycia Therapeutics, Inc. in 2019, and Enable Biosciences, Inc. in 2016, where she worked as Chairman.
Dr. Bertozzi also founded Firefly Bio, Inc. Dr. Bertozzi also currently works at Grace Science Foundation, as Director, OmniAb Operations, Inc., as Independent Director, OmniAb, Inc., as Independent Director from 2022, Stanford Chem-H, as Director from 2021, Xaira Therapeutics, Inc., as Director, Eli Lilly & Co., as Independent Director from 2025, Stanford University, as Professor, American Chemical Society, as Member, The Royal Society, as Member, Howard Hughes Medical Institute, Inc., as Professor, National Academy of Sciences, as Member, American Academy of Arts & Sciences, as Member, National Academy of Medicine (United States), as Member, American Society for Biochemistry & Molecular Biology, Inc., as Member, Accademia Nazionale dei Lincei, as Member, and National Academy of Inventors, as Member.
Dr. Bertozzi also formerly worked at Eli Lilly & Co., as Independent Director from 2017 to 2021, Lawrence Berkeley National Laboratory, as Director-Molecular Foundry, The Broad Institute, Inc., as Director, Catalent, Inc., as Director, Molecular Foundry, as Director, Alnylam Pharmaceuticals, Inc., as Independent Director from 2023 to 2025, and the University of California, Berkeley, as Professor from 1996 to 2015.
Dr. Bertozzi received her doctorate degree in 1993 from the University of California, Berkeley.